查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1495990

藥物傳輸市場 - 2024 年至 2029 年預測

Drug Delivery Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 132 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年給藥市場的市場規模為8,352.17億美元，預計預測期內複合年成長率為8.90%，2029年市場總合規模達15,169.44億美元。

藥物輸送裝置是用於控制和標靶釋放藥物的專用裝置。儘管幾個世紀以來藥物一直在提供健康益處並延長壽命，但近幾十年來藥物的傳遞方式發生了變化。分子生物學策略可用於發現透過與藥物非標靶的身體部位相互作用來耐受副作用的藥物。藥物傳輸系統可控制藥物的釋放量和到達目標的距離。

慢性病盛行率的增加、醫療診斷市場的成長、技術進步和新公司的推出正在推動市場成長。根據世界衛生組織 (WHO) 預測，到 2020 年，慢性病盛行率預計將增加 57%。

此外，由於冠狀病毒大流行，多家製藥公司對感染疾病治療的需求激增，這是拉動藥品輸送需求的主要因素。

此外，人們對藥物輸送系統的認知不斷提高也有助於市場成長。此外，藥物輸送市場的成長也受到醫療保健和政府資金增加等其他因素的影響。此外，需要使用藥物輸送系統的各種慢性疾病的出現已成為藥物傳輸系統市場的主要促進因素。然而，藥物輸送市場因藥物召回和缺陷的增加而受到阻礙。

新興經濟體也具有很高的成長潛力，這應該會在預測期內提供利潤豐厚的機會。許多藥物和疫苗正在進行各種臨床試驗，預計在未來幾個月和幾年內根據治療 COVID-19 的緊急使用授權指南向患者提供。疫苗正在大規模開發、製造和管理，導致預測期內對各種藥物輸送系統的需求增加。

市場促進因素：

  • 生技藥品需求的成長預計將推動藥物輸送市場的發展。

生技藥品是治療多種疾病和病症的尖端治療方法。根據世界衛生組織（WHO）統計，每年約有4,100萬人死於慢性病，其中約1,790萬人死於心血管疾病，其次是癌症（900萬人）、呼吸道疾病（390萬人）和糖尿病（ 160萬人）。此外，大約80%的慢性病死亡是由這四類人群造成的。老年人口的成長也意味著慢性病影響更多的人，增加了對生技藥品的需求。 65 歲及以上人口將從 2019 年的十分之一 (9%) 增加到 2050 年的六分之一 (16%)（資料來源：世界衛生組織）。投資者也在推動整體市場的成長。

此外，在新加坡，諾華公司投資7億美元建立生技藥品中心，百時美施貴寶投資超過9億美元在愛爾蘭建設大型生技藥品設施，並於2019年開幕。未來幾年，由於生技藥品市場的顯著成長以及非專利藥注射劑主要透過注射給藥的事實，注射給藥市場應該會進一步成長。

市場限制因素：

  • 針刺傷可能會阻礙藥物輸送市場的成長。

與注射給藥相關的主要風險之一是針刺傷。根據 Pharma Jet 報道，美國每年報告 60 萬至 80 萬起針刺傷事件。美國職業安全與健康管理局 (OSHA) 估計，美國有 560 萬名工人因針刺傷而面臨接觸血源性病原體的風險。此外，CDC 估計美國醫院每年發生 385,000 起針刺傷。

此外，世衛組織發現，全世界醫護人員中 34.7% 的B型肝炎病例、56.9% 的C型肝炎病例和 46.7% 的愛滋病毒/愛滋病病例與針刺傷有關。

主要進展：

  • 2023 年 2 月：愛爾蘭研發公司 Innovation Zed 的 InsulCheck DOSE附加元件設備獲得 CE 標誌，該設備可自動記錄胰島素筆用戶的給藥時間和劑量次數。這種不顯眼的設備可以捕捉劑量、注射事件時間戳記、溫度、連接/移除事件，並將資料即時傳輸到相容的顯示裝置。 SHL Medical 和 SHL Technologies 的聯合開發也解決了注射筆設計中的相容性挑戰。
  • 2023 年 1 月 - 法國 Biocorp 的 SoloSmart® 獲得 FDA 批准，SoloSmart® 是賽諾菲拋棄式胰島素筆的智慧帽。這是 Biocorp 的 Mallya 平台第二次獲得 FDA 批准。 SoloSmart 連接您的 SoloStar® 胰島素筆，自動記錄關鍵治療資訊並將其發送到您的數位應用程式。這使得醫療保健專業人員可以更輕鬆地在多次治療期間追蹤患者。 FDA 的批准加強了 BioCorp 在智慧筆市場的技術領先地位。 SoloSmart 將於 2020 年開始銷售，是 Biocorp連網型解決方案組合的一部分。
  • 2022 年 9 月 - BD 推出用於疫苗生產的新一代玻璃預充式注射器 (PFS)，既可靠又有效率。 BD EffivaxTM 玻璃預充式注射器是與一家製藥公司合作開發的，旨在滿足疫苗生產的複雜需求。百強生物製藥公司中有70% 依賴BD 的PFS 供應，這種新設計提高了填充/完成和容器的可靠性，降低了生產線停機風險，並降低了總擁有成本、製造能力，並提高了可用性。
  • 2022 年 9 月—生物製藥公司 Corium 宣布了其每週一次的經皮製劑 ADLARITY 對老年失智症失智症的 1 期研究結果。在這項研究中，發現 ADLARITY 提供的藥物暴露量與口服多奈哌齊相當，且消化器官系統不利事件較少。 FDA核准了ADLARITY 5 毫克/天或 10 毫克/天的配方，使其成為第一個也是唯一一個每週一次的貼劑，可透過皮膚持續輸送固定劑量的多奈哌齊。
  • 2022 年 6 月 - 諾華收購 Kedalion Therapeutics 和 AcuStream(TM) 平台。 AcuStream(TM) 平台是一種局部眼科給藥裝置，專為某些局部眼科藥物的精確劑量和給藥而設計。不含防腐劑的電子機械有可能改善患者體驗並促進準確劑量。諾華計劃開發 AcuStream 技術，用於現有和未來的眼前治療，包括 Xiidra®，一種用於治療乾眼症的First-in-Class處方箋LFA 1 拮抗劑。 Kedalion Therapeutics 已完成由諾華主導的B 輪資金籌措，並擁有收購該公司及其 AcuStream 技術的獨家選擇權。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行概述

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球藥物輸送市場：依類型

  • 介紹
  • 吸入給藥
  • 注射給藥
  • 鼻腔給藥
  • 口服給藥
  • 經皮給藥

第6章全球藥物傳輸市場：依技術分類

  • 介紹
  • 無針注射器
  • 藥物輸送貼片
  • 自動注射器
  • 其他

第7章全球藥物輸送市場：依應用分類

  • 介紹
  • 癌症治療
  • 感染疾病治療
  • 其他

第8章全球藥物輸送市場：按地區

  • 介紹
  • 北美洲
  • 南美洲
  • 歐洲
  • 中東/非洲
  • 亞太地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Pfizer
  • Insulet Corporation
  • West Pharmaceutical Services, Inc.
  • Enable Injections
  • Mersana Therapeutics
  • Becton, Dickinson and Company
  • Recipharm AB
  • Medtronic
  • Boston Scientific Corporation
簡介目錄
Product Code: KSI061612100

The drug delivery market was valued at US$835.217 billion in 2022 and is expected to grow at a CAGR of 8.90% over the forecast period to reach a total market size of US$1,516.944 billion by 2029.

A drug delivery device is a specialized device for the controlled and targeted release of drugs. Drugs have been extending health benefits and lifespans for centuries, and the way medicines are delivered has changed over the last few decades. Molecular biology strategies can be used to discover a medication that has acceptable side effects due to interacting with parts of the body that are not targeted by the drug. Systems for delivering drugs control how much of the drug is released and how far it reaches the target.

Increasing incidences of chronic diseases, growth in the medical diagnostics market, advancements in technology, and new company launches are driving the market growth. Globally, chronic disease prevalence is expected to rise by 57% by 2020, according to the World Health Organization.

Additionally, several pharmaceutical companies are suddenly experiencing a surge in demand for drugs designed to treat infectious diseases because of the Coronavirus outbreak globally, which has been a major factor boosting the drug delivery demand.

The growing awareness surrounding pharmaceutical drug delivery systems is also contributing to the market growth. Furthermore, the pharmaceutical drug delivery market growth is being influenced by additional factors such as an increase in healthcare and government funding. In addition, the emergence of various chronic diseases, which necessitate the use of pharmaceutical delivery systems, is a key driver of the pharmaceutical delivery systems market. The drug delivery market is, however, hindered by the increasing number of drug recalls and failures.

Additionally, the forecast period should see lucrative opportunities in developing economies due to their high growth potential. A great number of drugs and vaccines are undergoing various clinical trials and are expected to be made available to patients in the coming months and years under guidelines for emergency usage authorizations for COVID-19 treatment. Vaccines are being developed, manufactured, and administered at a mass level, which is resulting in high demand for different drug delivery systems over the forecast period.

Market Drivers:

  • Growth in the biologics drug demand is anticipated to surge the drug delivery market.

Biologic drugs are the most advanced treatments available for a variety of illnesses and conditions. Approximately 41 million people die each year from chronic diseases, according to World Health Organization statistics, and about 17.9 million people die from cardiovascular disease, followed by cancer (9 million), respiratory diseases - 3.9 million, and diabetes - 1.6 million. Furthermore, approximately 80% of chronic disease deaths result from these four groups. The increasing number of geriatrics also means that chronic diseases will affect more people, thus increasing the demand for biologics. The number of people over the age of 65 will rise from one in 11 in 2019 to one in six by 2050 (16%), up from one in 11 at the beginning of this year (9%) (Source: WHO). Investors have also been driving the overall market growth.

Moreover, in Singapore, Novartis AG invested USD 700 million in the establishment of a biologics center, while Bristol-Myers Squibb spent more than USD 900 million on a large biologic facility in Ireland, which opened in 2019. In the coming years, due to the significant growth in the biologics market and the fact that generic injectables are mainly administered via injection, the injectable drug delivery market should witness further growth.

Market Restraint:

  • Injuries caused by needlesticks could hamper the drug delivery market growth.

One of the major risks associated with injectable drug delivery is needlestick injuries. According to Pharma Jet, 600,000-800,000 needlestick injuries are reported in the United States every year. The Occupational Safety and Health Administration (OSHA) estimates that 5.6 million workers in the US are at risk of being exposed to blood-borne pathogens because of needlestick injuries. In addition, the CDC estimates that US hospitals suffer 385,000 needlestick injuries annually.

In addition, the WHO found that 34.7% of cases of Hepatitis B, 56.9% of cases of Hepatitis C, and 46.7% of cases of HIV/AIDS among healthcare workers worldwide were associated with injuries caused by needlesticks.

Key Developments:

  • February 2023- Innovation Zed, an Irish R&D company, secured a CE Mark for the InsulCheck DOSE add-on device, which automatically logs the time and dialled doses for insulin pen users. The discreet device captures dose value, injection event time stamp, temperature, and mounting and unmounting events and sends real-time data to a compatible display device. It features a vibrant OLED screen for increased user engagement and was developed in collaboration with SHL Medical and SHL Technologies to address compatibility challenges in injection pen designs.
  • January 2023- Biocorp, a France-based company, received FDA clearance for SoloSmart(R), Sanofi's smart cap for disposable insulin pens. This marks the second FDA clearance for Biocorp's Mallya platform. SoloSmart connects SoloStar(R) insulin pens, automatically recording key treatment information and transmitting it to a digital application. It provides healthcare professionals with an easy way to follow patients during multitherapy treatments. The FDA's authorization reinforces Biocorp's technological leadership in the smart pens market. SoloSmart is available for sale from 2020 and is part of Biocorp's connected solutions portfolio.
  • September 2022- BD introduced a next-generation glass pre-fillable syringe (PFS) for vaccine manufacturing, designed for reliability and efficiency. The BD EffivaxTM Glass Prefillable Syringe, developed in collaboration with pharmaceutical companies, is designed to meet the complex needs of vaccine manufacturing. With 70% of the top 100 biopharmaceutical companies relying on BD for PFS supply, the new design enhances fill/finish and container reliability, reducing line stoppage risk and improving total cost of ownership, manufacturing capacity, and supply availability. BD is benefited from a $1.2 billion investment to expand and upgrade manufacturing capacity and technology for PFS.
  • September 2022- Corium, a biopharmaceutical company, published phase 1 results for ADLARITY, a once-weekly transdermal system for Alzheimer's dementia patients. The study found that ADLARITY delivered drug exposure equivalent to oral donepezil, with lower gastrointestinal adverse events. The FDA approved ADLARITY in 5 or 10 mg/day formulations, making it the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin. The trial supports ADLARITY as a compliant and safe once-weekly dosing regimen for Alzheimer's dementia treatment.
  • June 2022- Novartis was acquired Kedalion Therapeutics and its AcuStream(TM) platform, a topical ocular delivery device designed for precise dosing and delivery of certain topical ophthalmic medications. The preservative-free, electromechanical device may improve patient experience and facilitate precise dosing. Novartis plans to develop AcuStream technology for use with existing and future front-of-eye therapies, including Xiidra(R), a first-in-class prescription LFA 1 antagonist for dry eye disease treatment. Kedalion Therapeutics completed its Series B financing led by Novartis, with an exclusive option to acquire the company and its AcuStream technology.

Market Segmentation:

By Type

  • Inhalation Drug Delivery
  • Injectable Drug Delivery
  • Nasal Drug Delivery
  • Oral Drug Delivery
  • Transdermal Drug Delivery

By Technique

  • Needle-free injectors
  • Drug delivery patches
  • Autoinjectors
  • Others

By Application

  • Cancer treatment
  • Infectious diseases treatment
  • Others

BY Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL DRUG DELIVERY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Inhalation Drug Delivery
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Injectable Drug Delivery
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Nasal Drug Delivery
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Oral Drug Delivery
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Transdermal Drug Delivery
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL DRUG DELIVERY MARKET BY TECHNIQUE

  • 6.1. Introduction
  • 6.2. Needle-free injectors
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Drug delivery patches
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Autoinjectors
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL DRUG DELIVERY MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cancer treatment
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Infectious diseases treatment
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Others
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness

8. GLOBAL DRUG DELIVERY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Technique
    • 8.2.3. By Application
    • 8.2.4. By Country
      • 8.2.4.1. USA
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Technique
    • 8.3.3. By Application
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Technique
    • 8.4.3. By Application
    • 8.4.4. By Country
      • 8.4.4.1. Germany
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. France
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. United Kingdom
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Spain
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
      • 8.4.4.5. Others
        • 8.4.4.5.1. Market Opportunities and Trends
        • 8.4.4.5.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Technique
    • 8.5.3. By Application
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Technique
    • 8.6.3. By Application
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Pfizer
  • 10.2. Insulet Corporation
  • 10.3. West Pharmaceutical Services, Inc.
  • 10.4. Enable Injections
  • 10.5. Mersana Therapeutics
  • 10.6. Becton, Dickinson and Company
  • 10.7. Recipharm AB
  • 10.8. Medtronic
  • 10.9. Boston Scientific Corporation